Syndax Pharmaceuticals' clinical trial for idiopathic pulmonary fibrosis failed, and the stock price plummeted 34% after the market.

Zhitongcaijing · 1d ago
Syndax Pharmaceuticals' clinical trial for idiopathic pulmonary fibrosis failed, and the stock price plummeted 34% after the market.